Increased secretion of glucagon
ICD-10 E16.3 is a billable code used to indicate a diagnosis of increased secretion of glucagon.
Increased secretion of glucagon is a condition characterized by elevated levels of glucagon, a hormone produced by the alpha cells of the pancreatic islets. Glucagon plays a crucial role in glucose metabolism by promoting gluconeogenesis and glycogenolysis, leading to increased blood glucose levels. This condition can be associated with various disorders, including hyperinsulinism, where excessive insulin secretion leads to hypoglycemia, prompting the pancreas to secrete more glucagon to counteract low blood sugar levels. Pancreatic islet disorders, such as glucagonoma, can also lead to increased glucagon secretion. Clinically, patients may present with symptoms of hyperglycemia, weight loss, and, in some cases, signs of diabetes mellitus. The management of increased glucagon secretion often involves addressing the underlying cause, which may include surgical intervention for tumors or medical management for metabolic disorders. Understanding the interplay between glucagon, insulin, and glucose metabolism is essential for effective diagnosis and treatment.
Detailed lab results showing glucagon levels, patient history of glucose metabolism disorders, and treatment plans.
Patients presenting with hypoglycemia, weight loss, or diabetes symptoms requiring glucagon assessment.
Endocrinologists must ensure comprehensive documentation of all metabolic parameters to support the diagnosis.
Pathology reports confirming the presence of glucagonoma or other islet cell tumors, imaging studies.
Patients with suspected pancreatic tumors presenting with hyperglycemia and weight loss.
Oncologists should document tumor characteristics and treatment plans to justify coding.
Used to assess glucose metabolism in patients suspected of glucagon excess.
Document fasting status and reason for testing.
Endocrinologists should correlate test results with clinical findings.
Common causes include glucagonoma, hyperinsulinism, and other pancreatic islet cell disorders. It can also occur as a compensatory response to hypoglycemia.
